Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20124 in Advanced Solid Tumors
NCT06763159Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of HS-20124 in solid tumor, ovarian cancer and renal cell carcinoma (RCC) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Objective tumor response for target lesions at 3 weeks, Objective Response Rate and 2 more. Started Oct 2024; status: recruiting.
02
Drugs
HS-20124
03
Conditions
solid tumorovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06763159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06763159.